Wednesday, May 18, 2016 7:47:08 AM
Again, look at AEZS for an example of how this works. Was at $10, even after the P3 CRL (which btw was for a small indication, non oncology), and then slipped to $5. The expectation there and reason people stayed invested was the P3 in endometrial cancer with topline expected late 2016. That's their biggie (like the DCVax L is NWBO's biggie). And nothing at all untowards has occurred in that study (by contrast the DCVax L P3 has been on hold for some 10 months now). The AEZS P3 was and is still very much on track.
All the "bad news" appeared to be priced in. Retailers were increasing their stakes, telling other unwitting retailers to do the same (sounds familiar?). And what happened? They got fleeced, that's what. They were diluted from $5 down to $0.05--they lost 99% of their investment! Then 100-1 R/S and they were literally robbed. While this happened there were NO fundamental changes at AEZS. Yet investors thinking they found a great entry lost 99%.
Now what happens if AEZS is ultimately successful in their P3? Well more warrants exercise and the float swells again, and even if the pps goes up to $50 from here (at $3s now) those investors will still be down 90%. That's right--90%...
So Adam's right. This will get worse. They must raise soon. Fantasies of anything good happening in the P3 on hold are only that. All signs point to them seeking massive changes or else terminating the study. The $0.85 will be sold at $0.60 to the next financer, then $0.45 to the next, etc. No tutes want this. The increases you've seen are all from larger funds adding in an array of small cap bios and Russell stocks, which includes NWBO (who may be dropped from the Russel btw).
So at some point they will probably make a major overhaul and revamp NWBO. And you all will truly be "bag holders" staring at over 95% loses you will never see a profit on no matter how successful NWBO ever one day becomes.
"Think for yourselves and let others enjoy the privilege to do so, too."
-Voltaire
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM